



Innovating Technologies for Life

ASX Announcement
24 October 2016

ITL BioMedical Announces Global Launch of DonorCare® Needle Guard 2

ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare® Needle Guard 2 will take place at the AABB Annual Meeting in Orlando, the premiere event for healthcare professionals in transfusion medicine and cellular therapies.

ITL has been selling the first generation DonorCare Needle Guard for over 15 years and has sold in excess of 200 million units in over 50 countries.

First generation DonorCare Needle Guard set a global industry standard for whole blood collection needle guards. The highly innovative DonorCare® Needle Guard 2 provides robust functionality with enhanced features including visual confirmation that the needle is safely locked in place, along with an audible click.



The DonorCare Needle Guard 2 design allows safe and fast needle withdrawal from any angle, immediately shielding whole blood collection needles and providing users a high level of protection from potential biohazard exposure and needlestick injury. Featuring a simple and user-friendly design, the product requires minimal training and can be easily incorporated into existing processes.

ITL BioMedical has also produced an efficient design that will enable manufacturers to pre-attach DonorCare Needle Guard 2 onto blood bag tubing.

Bill Mobbs, Executive Chairman of ITL BioMedical commented “It is very rewarding to take a global industry standard product up to the next level.

“As with all of our innovative products, DonorCare 2 needle guard was designed with end user input from the beginning, and we feel confident this product will be as successful as its predecessor.”

ITL Limited ABN 16 088 212 088
Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL’s patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL’s wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR
Innovative Companies Awards

Australian Securities Exchange
Code: ITD

Ordinary Shares
95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer
---------------	-------------------------

ITL Contact
Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com

www.itl-limited.com

Media
Ben Knowles Walbrook IR
Phone: +61 426 277 760
Email: ben.knowles@walbrookir.com.au

For personal use only



Innovating Technologies for Life

**ASX Announcement
24 October 2016**

About ITL BioMedical - ITLBioMedical.com.

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in blood collection centers and healthcare markets worldwide. For more information or inquiries, visit ITLBioMedical.com.

DonorCare® and SampLok® are registered trademarks of ITL Corporation, Melbourne, Australia. Copyright © 2016. All rights reserved.

For personal use only